AI in Pharma: 10 Use Cases, Real Examples, and a Safe Rollout Plan

What is AI in pharma?

AI in pharma is the use of machine-based systems to make predictions or recommendations, generate content, or carry out bounded tasks across drug research, development, manufacturing, safety monitoring, and commercialization. The term includes several technologies with different jobs:

• Machine learning finds patterns in historical data and predicts a defined outcome, such as compound activity or equipment failure.
• Natural language processing extracts and organizes information from sources such as scientific papers, clinical notes, safety reports, and regulatory documents.
• Computer vision analyzes images, including tissue slides, cell images, and manufacturing inspection data.
• Generative AI produces new text, molecular structures, images, code, or synthetic data from learned patterns.
• AI agents combine models with tools and workflows so they can retrieve records, schedule an action, update a system, or hold a conversation.

The technology label does not determine the risk. A language model that drafts an internal meeting summary has little influence on a product decision. The same model used to exclude a trial participant or write an unreviewed safety narrative could affect evidence or patient safety. The useful questions are: What exact task will the AI perform, how much authority will it have, and what happens when it is wrong?

The use of AI in the pharmaceutical industry is no longer hypothetical. The FDA says its Center for Drug Evaluation and Research reviewed more than 500 submissions with AI components from 2016 through 2023, spanning nonclinical, clinical, postmarketing, and manufacturing phases.

AI in pharma at a glance

This table is a starting map, not a case for automating every row. The best first project usually has a frequent pain point, a measurable baseline, enough representative data, and a clear human fallback.

10 practical AI use cases across the pharmaceutical lifecycle

1. Target identification and drug design

AI can connect information from omics data, disease pathways, chemical libraries, scientific literature, and prior experiments to rank targets or candidate compounds. Generative models can propose molecules subject to constraints such as potency, selectivity, solubility, or synthesizability. Predictive models can then prioritize which candidates deserve expensive laboratory work.

The output is a better experimental queue, not proof that a target is valid or a molecule is safe. Prospective wet-lab confirmation remains the decisive test. Teams should compare the AI-assisted process with the existing discovery funnel using confirmed hits, novelty, chemical diversity, failed synthesis attempts, and time to reproducible evidence—not the number of molecules generated.

2. Preclinical development and formulation

Machine learning can support absorption, distribution, metabolism, excretion, and toxicity predictions; help select formulations; and model relationships among ingredients, process parameters, and product quality. These applications may reduce the experimental search space and surface failure risks earlier.

Performance needs to be tested on compounds, formulations, and conditions that reflect the intended use. A model may look accurate because near-duplicate compounds appear in both training and test data. Time-aware splits, scaffold-aware evaluation, uncertainty estimates, and prospective experiments make the result more credible. AI can prioritize experiments, but it should not be presented as a blanket replacement for required nonclinical evidence.

3. Clinical trial design, recruitment, and operations

AI can compare protocol language, simulate the effect of eligibility criteria, estimate site feasibility, search records for possible participants, prioritize data queries, and forecast dropout risk. Generative AI can draft administrative documents, while conversational agents can support approved recruitment outreach, scheduling, and visit reminders.

The safe pattern is assisted review. A match should place a record in a coordinator's queue rather than independently enrolling or excluding a person. NIH researchers evaluated TrialGPT as an assistant for patient-trial matching; in a small physician pilot, it reduced aggregate screening time by 42.6% while keeping experts in the loop. The published TrialGPT study supports assisted screening, not autonomous eligibility decisions.

Site and participant models also need subgroup analysis. An aggregate enrollment lift can hide higher false-negative rates for populations underrepresented in the source data. Measure referral, screening, enrollment, retention, and error rates by relevant site and participant group. Our detailed guide to AI in clinical trials covers evidence generation, participant communication, and validation in greater depth.

4. Precision medicine and real-world evidence

Models can combine genomic, imaging, laboratory, clinical, and behavioral data to identify phenotypes, estimate outcomes, and explore which subgroups may respond differently. They can also extract variables from electronic health records or claims for real-world evidence analyses.

These are difficult causal and measurement problems. A model that predicts which treatment a patient historically received does not necessarily predict which treatment will benefit a future patient. Confounding, missing data, changes in clinical practice, and unequal access to care can all create misleading patterns. Define the clinical question first, distinguish prediction from causal inference, and validate the full data pipeline in the population and setting where the output will be used.

5. Regulatory intelligence and document workflows

Language models can search prior submissions, compare labels or guidance, extract structured fields, summarize agency correspondence, translate approved material, and prepare a first draft with links back to source passages. Used well, generative AI gives subject-matter experts a faster starting point.

The model should never silently fill a gap. Require source-linked output, controlled reference collections, a named reviewer, document version history, and an unsupported-claim test. Final protocols, consent materials, safety narratives, labels, and submissions remain under accountable human approval. For high-impact work, preserve the input, retrieval result, model and prompt version, draft, reviewer changes, and final disposition.

6. Pharmaceutical manufacturing and quality control

AI in pharmaceutical manufacturing can analyze process and sensor data to detect anomalies, predict equipment maintenance, improve visual inspection, or recommend process adjustments. Digital twins and multivariate models can help teams understand how material attributes and process parameters affect critical quality attributes.

This is not ordinary office automation. A recommendation that changes a controlled manufacturing process must fit the site's pharmaceutical quality system, validation approach, access controls, audit trail, and change-control process. The FDA's discussion paper on AI in drug manufacturing identifies opportunities as well as questions around model lifecycle management, cloud applications, explainability, and regulatory oversight.

Start with advisory or monitoring use when possible. Compare alerts with confirmed deviations and maintenance events, measure false negatives as well as false positives, and define what the system does when a sensor, data feed, or model is unavailable.

7. Supply-chain planning and risk detection

AI can forecast product demand, identify likely shortages, monitor cold-chain or logistics exceptions, optimize inventory, and prioritize supplier risks. The benefit is a faster response to changing signals across production, distribution, and demand.

Historical optimization is not resilience. Pandemics, launches, recalls, geopolitical shocks, and abrupt prescribing changes may lie outside the training data. Planners need scenario analysis, confidence ranges, manual overrides, and an escalation path for low-confidence forecasts. The business case should measure service level, stockouts, waste, forecast error, and the cost of unnecessary intervention.

8. Pharmacovigilance and safety operations

Natural language processing can extract suspect products, events, dates, outcomes, and reporter details from incoming narratives. Models can help find duplicates, code terms, prioritize cases, or surface patterns for review. Automation is especially useful at intake, where information arrives through forms, email, literature, call centers, and partners.

Priority is not disposition. Qualified safety staff determine whether a case is valid, serious, expected, related, or reportable. A production system needs high recall, explicit handling for uncertainty, preserved source records, and rapid human escalation. Evaluate performance by source, language, product, event type, and seriousness; a favorable overall accuracy can conceal the rare missed case that matters most.

9. Medical affairs, marketing, and field enablement

AI in pharma marketing can help segment audiences, select the next approved content, summarize an interaction, identify unanswered questions, and help field teams find material in a controlled knowledge base. Medical affairs teams can use similar retrieval and summarization patterns for literature monitoring and medical-information workflows.

The control boundary is approved content and intended audience. A fluent model can improvise an unsupported efficacy comparison or drift into off-label discussion. Retrieval should use the current approved corpus, responses should retain source references, and uncertain or unsolicited medical questions should route to the appropriate team. Medical, legal, and regulatory review still governs externally visible claims.

10. Voice AI for service and operational communication

Voice AI can handle structured, high-volume conversations without requiring every caller to use an app or portal. Suitable patterns include scheduling a site or support call, confirming a delivery window, collecting a requested callback time, routing a medical-information inquiry, delivering an approved reminder, or transferring a complex conversation to trained staff.

Keep the agent outside clinical judgment. It can capture what a caller says, but it should not diagnose symptoms, determine eligibility, decide whether an adverse event is reportable, or invent product guidance. A strong workflow uses approved scripts and knowledge, minimum necessary data, deterministic permissions for every system update, clear AI disclosure, opt-out handling, and an immediate human handoff for safety, medical, consent, or out-of-scope questions.

For a possible safety report, the agent should preserve the caller's wording, collect only the approved fields, and trigger the organization's safety procedure and staff handoff. It should not downgrade the report because the conversation sounds routine.

Real examples of AI in pharma

The most useful examples show what the system actually influenced and what evidence still had to be produced.

An AI-discovered and AI-designed drug reached a phase 2a trial

Rentosertib, an investigational treatment for idiopathic pulmonary fibrosis, used AI in both target identification and molecular design. A 2025 paper reported results from a randomized phase 2a trial. The Nature Medicine study is a meaningful milestone: an AI-enabled discovery program progressed into controlled clinical testing.

It is not evidence that an algorithm can skip development. The candidate still required synthesis, nonclinical work, phase 1 testing, and a randomized trial. AI accelerated parts of the search; the conventional evidence pathway tested the resulting drug.

FDA qualified its first AI-based drug development tool

In December 2025, the FDA qualified AIM-NASH, an AI tool that assists pathologists by analyzing liver-biopsy images and providing standardized scores for metabolic dysfunction-associated steatohepatitis clinical trials. The qualification applies to a defined context of use. It is not blanket approval of the algorithm for every disease, image, or decision.

That distinction is central to trustworthy AI: validate a specific model for a specific input, user, output, and decision.

AI-assisted trial matching reduced screening time in a controlled pilot

The TrialGPT example above shows a different kind of value. Rather than creating a new medicine or endpoint, the model organized eligibility evidence for physician review. Its benefit was workflow time, and the study design retained expert judgment. This is often the more realistic first deployment pattern for generative AI in pharma.

Benefits and limitations of AI in the pharmaceutical industry

The main benefits come from reducing the cost of search and coordination:

• A smaller experimental search space: Rank the compounds, targets, formulations, records, or documents most worth expert attention.
• Earlier signals: Detect anomalies, possible safety cases, operational delays, or supply risks sooner.
• More consistent execution: Apply the same extraction, comparison, or routing procedure across large volumes.
• Faster knowledge access: Connect an answer or draft to the supporting source material.
• Scalable communication: Handle routine interactions while preserving a path to a qualified person.

The disadvantages of AI in pharma are equally practical:

• Biased or incomplete data: Historical data reflect who was measured, treated, recruited, or reported—not every population the model will encounter.
• Data leakage and weak evaluation: A model can appear accurate when its test set is too similar to its training data or contains information unavailable at decision time.
• Hallucination and automation bias: Generative models can make unsupported text sound certain, while users may defer to an output because it looks polished.
• Drift and version changes: New products, populations, equipment, source systems, prompts, and foundation models can change performance.
• Poor traceability: A result is hard to defend when the organization cannot reconstruct its input, model version, sources, reviewer, and downstream action.
• Security and privacy exposure: More integrations and data access create more paths for unauthorized disclosure or action.
• Unclear accountability: A vendor can provide software, but the regulated organization still needs an owner for the use, evidence, review, and failure response.

AI is valuable when the workflow is designed around these limits rather than treating them as a disclaimer.

What FDA's current direction means for pharma AI teams

In January 2025, the FDA issued draft guidance on AI used to produce information or data that supports regulatory decisions about a drug's safety, effectiveness, or quality. Its risk-based credibility framework starts with the question of interest and the model's context of use, then considers model influence, the consequence of a wrong decision, and the evidence needed to establish credibility.

In January 2026, the FDA and European Medicines Agency published 10 guiding principles of good AI practice in drug development. Their lifecycle approach emphasizes human-centric design, a risk-based framework, multidisciplinary expertise, data governance and documentation, clear context of use, suitable model development and performance assessment, and lifecycle management.

For implementation teams, that direction translates into five operating rules:

1. Define the context of use. Name the user, input, output, population, environment, decision, and downstream action.
2. Scale evidence to influence and consequence. A source-linked internal draft and an AI-derived endpoint do not need the same validation package.
3. Validate the complete system. Test data pipelines, interfaces, permissions, human review, downtime behavior, and audit records—not only the model.
4. Control change. A new model, threshold, prompt, retrieval corpus, sensor, or integration can change the validated use.
5. Engage the relevant regulator early for high-impact uses. Do not wait until a submission to discover that the context, evidence, or change plan is inadequate.

Regulatory expectations vary by product, market, data, and use. This article is an implementation framework, not legal or regulatory advice.

A practical rollout plan for AI in pharma

1. Start with the workflow, not the model

Write one problem statement with a baseline. “Use generative AI in clinical operations” is too broad. “Reduce the time coordinators spend finding possible matches without automatically excluding any record” is testable.

Name the current volume, cycle time, error rate, cost, and owner. If there is no baseline, a polished demo can be mistaken for improvement.

2. Decide how much authority the AI needs

Use the least influential role that can create value:

3. Map data, rights, and failure impact

Document the source, lawful or authorized use, quality, population coverage, identifiers, retention, access, and destination of every field. Separate missing data from negative values. Check whether users can correct the record and whether the model sees information that will be unavailable in production.

Then ask what a false positive, false negative, fabricated statement, duplicated action, outage, or unauthorized disclosure would do. Design the escalation and safe state before the happy path.

4. Set acceptance criteria before the pilot

Select metrics that match the consequence. A safety-intake model may prioritize recall and timely staff review. A document assistant needs citation correctness and a low unsupported-claim rate. A voice agent needs task completion, opt-out capture, transfer success, and zero unauthorized record changes.

Evaluate by relevant subgroup, site, source, language, product, and time period. Average accuracy is rarely enough.

5. Test prospectively in the complete workflow

Begin with retrospective evaluation, then use shadow mode or mandatory review under real operating conditions. Test missing fields, ambiguous language, prompt injection, unavailable tools, duplicated events, failed transfers, model timeouts, and updates to upstream systems.

Record not only what the model said, but which sources it used, which tool it requested, whether policy allowed it, what the reviewer changed, and what the system of record ultimately did.

6. Promote gradually and monitor the lifecycle

Limit the first production release by population, site, product, language, or action. Keep a kill switch and a manual path. Track drift, overrides, escalations, corrections, incidents, model and prompt versions, and business outcomes. Material changes return to validation rather than bypassing it as a routine software update.

Where Dasha fits in a pharma AI stack

Dasha is a platform for building real-time voice and text AI agents. For pharmaceutical teams, its appropriate role is the communication and workflow layer—not molecule design, clinical judgment, or regulatory decision-making.

Technical teams can use Dasha's managed voice AI runtime for inbound or outbound phone workflows, connect approved business actions through tools and webhooks, and transfer a caller to staff when the conversation reaches a clinical, safety, consent, privacy, or policy boundary. The customer backend should remain the authority for identity, permissions, approved content, record changes, and audit retention.

A bounded pharma workflow should:

1. identify the organization and disclose that the person is speaking with an AI agent;
2. confirm the approved contact and permission state before disclosing sensitive information;
3. use only the approved script, knowledge sources, and actions for that program;
4. treat each model-requested action as a proposal that a deterministic service authorizes;
5. preserve opt-outs and communication preferences immediately;
6. transfer medical, safety, consent, distress, and out-of-scope questions to qualified staff;
7. create an explicit failure task if the transfer or system update does not complete; and
8. retain the customer-approved trace of the conversation, tool request, policy result, and handoff.

Technical capability is not a compliance certification. Dasha does not currently publish a HIPAA BAA, SOC 2 Type II attestation, ISO 27001 certification, or documented retention, residency, and subprocessor terms. A SOC 2 Type II audit is in progress. Before using Dasha for protected health information or another regulated workload, review the current security and compliance status and contact the security team about available agreements and requirements.

Frequently asked questions about AI in pharma

What is the best AI tool for the pharmaceutical industry?

There is no single best tool. Molecule generation, image analysis, safety intake, document review, forecasting, and voice automation require different models, evidence, integrations, and controls. Select a tool by its performance in the defined context of use, data boundaries, traceability, change control, security posture, integration fit, and failure handling—not by a generic benchmark.

How is generative AI used in pharma?

Generative AI can propose molecular structures, summarize research, draft source-linked documents, translate approved material, create software code, and power conversational interfaces. Its outputs need review appropriate to their influence. Generated content should not enter a protocol, submission, label, safety decision, or external product communication merely because it is fluent.

How does AI help drug discovery?

AI can rank targets, predict molecular properties, generate candidate structures, and prioritize experiments. This can reduce the search space and improve the order in which teams test ideas. Laboratory reproduction, nonclinical evidence, and clinical trials are still required to determine whether the resulting drug is safe and effective.

Will AI replace pharmacists or pharma professionals?

AI is more likely to change task allocation than remove accountable professionals. It can handle high-volume search, extraction, prediction, drafting, and routing. Scientists, clinicians, pharmacists, safety specialists, quality teams, and regulatory professionals still define the question, review evidence, resolve exceptions, make high-impact judgments, and remain accountable for the result.

What is the biggest risk of AI in pharma?

The biggest risk is not one model error; it is giving an insufficiently validated model too much influence without a reliable way to detect, review, and contain the error. A narrow context of use, risk-based evidence, human oversight, deterministic authorization, traceability, and lifecycle monitoring reduce that risk.

Can voice AI be used in pharmaceutical operations?

Yes. Voice AI can support approved scheduling, reminders, routing, status calls, and other bounded interactions. It should disclose its role, minimize data, respect consent and opt-outs, use approved information, and escalate clinical or safety questions. Before any regulated deployment, confirm the legal, privacy, security, and vendor-agreement requirements for the exact workflow and jurisdiction.

Choose a narrow use case and make it measurable

AI in pharma creates value when it helps a specific team make a defined workflow faster, more consistent, or more informative without obscuring who is responsible. Start with one context of use, a real baseline, limited authority, prospective evidence, and a tested human fallback. Expand only after the system performs safely under the conditions in which it will actually operate.

If voice communication is the selected workflow, explore Dasha's voice AI backend and its getting-started path. For a regulated use, review Dasha's current security posture first and validate the complete customer-operated workflow before production.